Open access
Announcement
28 February 2013

Complete Genome Sequence of a Highly Virulent Newcastle Disease Virus Currently Circulating in Mexico

ABSTRACT

The complete genome sequence was determined for a highly virulent Newcastle disease virus strain from vaccinated chicken farms in Mexico during outbreaks in 2010. On the basis of phylogenetic analysis this strain was classified into genotype V in the class II cluster that was closely related to Mexican strains that appeared in 2004–2006.

GENOME ANNOUNCEMENT

Newcastle disease (ND) is a highly contagious viral disease in avian species and causes large economic losses in the poultry industry. Newcastle disease virus (NDV) is a member of the genus Avulavirus in the family Paramyxoviridae. The genome of NDV is a single-stranded, negative-sense, nonsegmented RNA with six genes encoding seven major viral proteins (1). NDV strains are divided into two classes based on genetic analysis: class I strains have been isolated mainly from wild birds and are generally avirulent, whereas class II strains have been recovered from wild and domestic birds and include virulent and avirulent isolates (2). Class I and II viruses are divided into 9 and 11 genotypes, respectively (3). Currently circulating strains in chickens around the world are genotypes V, VI, and VII of class II. Although all commercial chickens are routinely vaccinated with live NDV vaccine B1 or LaSota, ND continues to be a major problem for the poultry industry (4).
In North America, Mexico is the only country where highly virulent NDV strains are circulating (4). In 2010, NDV outbreaks affected chicken farms located in the states of Coahuila and Durango in North Central Mexico, in an agricultural region known as La Laguna in Mexico. ND outbreaks occurred in commercial vaccinated chickens, causing up to 24% to 36% mortality. Tissue samples, including tissue from lungs, trachea, spleen, and cecal tonsils, were taken from dead and sick broilers exhibiting central nervous system (CNS) signs and severe dyspnea. One of the isolates, namely, Mexico/01/10, was purified, and the genome sequence was determined by reverse transcription (RT)-PCR using overlapped consensus primers and direct sequencing. The 3′ and 5′ termini were determined by rapid amplification of cDNA ends (RACE) (5). The complete genome of Mexico/01/10 is 15,192 nucleotides in length. The amino acid sequence identities of fusion (F) and hemagglutinin-neuraminidase (HN) proteins between Mexico/01/10 and Mexican strains isolated in 2004–2006 are 99% and 98%, respectively (6, 7). However, the amino acid sequence identity of the F and HN proteins between Mexico/01/10 and the currently used vaccine strain LaSota is 89%. This indicates that the circulating strains are substantially distinct from the vaccine strain in use and suggests that antigenic differences contributed to poor vaccine protection.
The sequence of the F protein cleavage site is a major determinant of NDV pathogenicity. The cleavage sites of virulent NDV strains usually contain multiple basic residues, whereas avirulent strains have fewer basic residues (8, 9). The Mexican isolate has a virulent pathotype: RRQKR↓F (underlining represents the basic residue; arrow represents the site of cleavage). Phylogenetic analysis of the complete coding region of the F gene constructed by MEGA4.0 indicated that it was within genotype V in class II and is more closely related to Mexico isolates that appeared in 2004–2006, demonstrating that the highly virulent NDV strains are still circulating in Mexico with minor genetic variations.

Nucleotide sequence accession number.

The complete genome sequence of Mexico/01/10 has been deposited in GenBank under the accession number JX974435.

ACKNOWLEDGMENTS

This work was supported by NIAID contract N01A060009 (85% support) and the NIAID, NIH, Intramural Research Program (15% support).
The views expressed herein do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government.

REFERENCES

1.
Lamb R and Parks G. 2007. Paramyxoviridae: the viruses and their replication, p 1449–1496. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, and Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2.
Czeglédi A, Ujvári D, Somogyi E, Wehmann E, Werner O, and Lomniczi B. 2006. Third genome size category of avian paramyxovirus serotype 1 (Newcastle disease virus) and evolutionary implications. Virus Res. 120:36–48.
3.
Miller PJ, Decanini EL, and Afonso CL. 2010. Newcastle disease: evolution of genotypes and the related diagnostic challenges. Infect. Genet. Evol. 10:26–35.
4.
Samal SK. 2011. Newcastle disease and related avian paramyxoviruses, p 69–114. Samal SK, The biology of paramyxoviruses. Caister Academic Press, Norfolk, United Kingdom.
5.
Xiao S, Paldurai A, Nayak B, Subbiah M, Collins PL, and Samal SK. 2009. Complete genome sequence of avian paramyxovirus type 7 (strain Tennessee) and comparison with other paramyxoviruses. Virus Res. 145:80–91.
6.
Absalón AE, Mariano-Matías A, Vásquez-Márquez A, Morales-Garzón A, Cortés-Espinosa DV, Ortega-García R, and Lucio-Decanini E. 2012. Complete genome sequence of a velogenic Newcastle disease virus isolated in Mexico. Virus Genes 45:304–310.
7.
Perozo F, Merino R, Afonso CL, Villegas P, and Calderon N. 2008. Biological and phylogenetic characterization of virulent Newcastle disease virus circulating in Mexico. Avian Dis. 52:472–479.
8.
Panda A, Huang Z, Elankumaran S, Rockemann DD, and Samal SK. 2004. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb. Pathog. 36:1–10.
9.
Peeters BP, de Leeuw OS, Koch G, and Gielkens AL. 1999. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73:5001–5009.

Information & Contributors

Information

Published In

cover image Genome Announcements
Genome Announcements
Volume 1Number 128 February 2013
eLocator: 10.1128/genomea.00177-12

History

Received: 5 December 2012
Accepted: 18 December 2012
Published online: 28 February 2013

Contributors

Authors

Sa Xiao
Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA
Anandan Paldurai
Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA
Baibaswata Nayak
Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA
Armando Mirande
Supervet, Inc., The Woodlands, Texas, USA
Peter L. Collins
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Siba K. Samal
Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA

Notes

Address correspondence to Siba K. Samal, [email protected].

Metrics & Citations

Metrics

Note:

  • For recently published articles, the TOTAL download count will appear as zero until a new month starts.
  • There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
  • Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy